Endoscopic papillary balloon dilatation less than three minutes for biliary stone removal increases the risk of post-ERCP pancreatitis

Chung-Kai Chou\textsuperscript{1,2,3}, Kuei-Chuan Lee\textsuperscript{1,2,*}, Jiing-Chyuan Luo\textsuperscript{1,2,*}, Tseng-Shing Chen\textsuperscript{1,2}, Chin-Lin Perng\textsuperscript{1,2}, Yi-Hsiang Huang\textsuperscript{1,2}, Han-Chien Lin\textsuperscript{1,2}, Ming-Chih Hou\textsuperscript{1,2}

1 Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans’ General Hospital, Taipei, Taiwan, 2 Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, 3 Division of Gastroenterology, Department of Medicine, National Yang-Ming University Hospital, Ilan, Taiwan

* kclee2@vghtpe.gov.tw (KCL); jcluo@vghtpe.gov.tw (JCL)

Abstract

Objectives
The adequate duration for EPBD was unclear. Therefore, we aimed to investigate the effect of balloon dilatation duration of EPBD on the occurrence of PEP.

Methods
One hundred and ninety-eight patients with common bile duct (CBD) stone treated by EPBD were retrospectively recruited. The dilatation duration was determined according to adequate opening of the biliary orifice without bleeding. The clinical outcomes and complications of EPBD were recorded.

Results
We stratified the patients according to dilatation duration (Group A, <3 minutes; Group B, 3–5 minutes; Group C, ≥5 minutes). The group C patients had a higher proportion of large CBD stones (stones ≥10 mm) (33.3% vs. 26.8% vs. 53.5%, p = 0.01). Patients in group A had a significantly higher PEP rate than patients in group B (13.3 vs. 3.1, p = 0.032). There were no significant differences in perforation and bleeding rate among the three groups. Univariate and multivariate analyses showed that a dilatation duration of <3 minutes, CBD diameter < 10 mm and age ≥ 75 years were independent risk factors of PEP in post-EPBD patients.

Conclusions
In patients receiving EPBD, dilatation duration <3 minutes, lower CBD diameter, and younger age were independent risk factors of PEP.
Introduction

Choledocholithiasis, or common bile duct (CBD) stones, is a common disease globally. Endoscopic retrograde cholangiopancreatography (ERCP) with biliary endoscopic sphincterotomy (EST) has become the preferred therapeutic procedure for CBD stone removal. Endoscopic papillary balloon dilation (EPBD) was developed as a comparable alternative method to EST since the 1990s [1, 2]. Because of a lower risk of bleeding and preservation of papillary function [3], EPBD is comparable to EST for stone extraction, though it may require more endoscopic mechanical lithotripsy (EML) [4–6]. Furthermore, EPBD is usually preferred in younger patients or patients with coagulopathy [7, 8].

However, the biggest concern of EPBD is the increased rate of post-ERCP pancreatitis (PEP) [4, 5, 9, 10]. Some studies have found that the duration of EPBD was inversely associated with the risk of PEP [11]. However, the adequate dilatation time is still unclear. A randomized trial by Liao et al. found that the risk of PEP was lower with a 5-minute EPBD than with a 1-minute EPBD (4.8% vs. 15.1%), with a relative risk of 0.32 [12]. Chan et al. performed large balloon dilatations alone without sphincterotomy in 247 patients with large CBD stones. The mean duration of the dilatation procedure was 4.7 minutes, and the PEP rate was 0.8% (2/247) [13]. Oh et al. compared endoscopic papillary large balloon dilatation (EPLBD) and EST for removal of large CBD stones, with a duration of balloon dilatation of 31.3 seconds and a PEP rate of 5.0% [14]. Additionally, a meta-analysis showed that short EPBD (≤1 minute) had a higher risk of pancreatitis (odds ratio, 3.87) [11]. Currently, it is understood that balloon dilatation ≤1 minute actually increases the risk of pancreatitis in patients with CBD stones less than 1 cm [11, 12]. A compartment syndrome from post-EPBD hemorrhage/edema with uncut Sphincter of Oddi has been the proposed mechanism for the increased risk of pancreatitis [12]. However, not every patient can tolerate dilatation-induced pain for more than 5 minutes. In our hospital, the EPBD or EPLBD (balloon size >10mm) was stopped when an adequate orifice was opened without active bleeding. In addition, in patients receiving EPLBD, there have been no studies investigating the association of balloon dilation time with PEP. Therefore, in this study, we aimed to investigate the effect of the balloon dilation time on the efficacy and complications of EPBD or EPLBD in the removal of bile duct stones.

Methods

Patients

Between November 2010 and October 2012, 198 patients who were admitted to Taipei Veterans General Hospital due to CBD stones and treated by EPBD/EPLBD were retrospectively reviewed. The diagnosis of CBD stone was made by an abdominal sonogram, computed tomography (CT) scan, or magnetic resonance cholangiopancreatography (MRCP). The Ethical Review Committee of the Taipei Veterans General Hospital approved this study.

Endoscopic papillary balloon dilation

The EPBD procedure was performed by three experienced endoscopists (KCL, JCL, and TSC, > 200 procedures/year) via a duodenoscope (Olympus, JF260V). The experienced endoscopist evaluated the papilla first. In general, we used a cannula (Olympus, StarTipV, PR-V418Q) first (n = 152). If a small orifice of the papilla was noted, we used a taper cannula (Olympus, StarTipV, PR-V220Q) (n = 46). If the cannula and taper cannula both failed, we tried a guidewire-assisted cannulation (Olympus, VisiGlide2, G-26—2545S). None of these patients received precuts due to difficult cannulations. A difficult cannulation was defined after 5 minutes or five attempts, or more than one pancreatic cannulation (n = 54, 27.3%) [15]. We used CRE™
Balloon Dilatation Catheters (Boston scientific) for papillary dilatation, the balloon sizes ranged 8-15mm. The termination of the dilatation was decided subjectively according to an adequate biliary orifice opened without bleeding, and the dilatation time was recorded by a timer. After papillary dilatation, the CBD stone was extracted by the single-use retrieval basket (Olympus, TetraCatchV, FG-V422PR) or the balloon extractor (CONMED, DURAglide3 stone balloon) with/without lithotripsy (Olympus, LithoCrushV and lithotripsy handle MAJ-441).

Data collection
Medical records were reviewed for data collection. The following data were collected: (1) patients characteristics, such as age, sex, underlying diseases, and previous abdominal surgery history; (2) laboratory data, such as complete blood cell counts, international normalized ratio (INR), and serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TB), alkaline phosphatase (Alk-P), γ-glutamyl-transferase (γ-GT), blood urea nitrogen (BUN), creatinine, measured by Rochi/Hitachi Modular Analytics Systems (Roche Diagnostics GmbH, Mannheim, Germany); (3) findings during the procedure, such as maximum CBD diameter, CBD stone size, pancreatic duct cannulation, balloon dilatation time, and the tool used for the stone removal (basket or extraction balloon); (4) procedure-related complications and mortality; and (5) in hospital mortality and causes of mortality.

Statistical analysis
All statistical analyses were performed using the SPSS 17.0 for Windows (SPSS. Inc., Chicago, IL, USA). Continuous variables were presented as mean ± standard deviation. Logistic regression was used to determine the effects of variables on post ERCP pancreatitis. Only variables with p-values proximal to 0.1 in the univariate analysis were selected for the multivariate analysis. The effects of categorical variables on the outcomes were tested by the chi-square test. A two-tailed p value < 0.05 was considered to be significant.

Results
Basic characteristics
In total, 198 patients with CBD stones were admitted to our hospital and treated by EPBD. The mean age was 71.2±15.0 years (range, 25–97 years), and 128 (64.6%) patients were male. We separated the patients into three groups according to dilatation duration (t, minutes) (Group A, t < 3; Group B, 3 ≤ t < 5; Group C: t ≥ 5).

The basic characteristics of the three groups are shown in Table 1. There was no significant difference in age, sex, body mass index, and underlying comorbidities. The clinical conditions before EPBD- including vital signs, blood cell counts, renal function, liver function, and biliary tract profile were not significantly different.

Dilatation time was associated with CBD stone size
The findings during the EPBD procedure are shown in Table 2. There were no significant differences in the maximum CBD diameter, proportion of juxtapapillary diverticulum, and lithotripsy used between the three groups. However, patients in Group C had a larger CBD stone size (9.1±4.2 vs. 8.2±3.8 vs. 11.0±5.7mm, p = 0.003) and higher proportion of larger CBD stone (stones ≥ 10mm: 33.3 vs. 26.8 vs. 53.5%, p = 0.01). These results imply that bigger CBD stones need more dilatation time for EPBD to stop bleeding and ensure orifice opening.
Table 1. Basic characteristics of the patients.

| Group                  | A ($t < 3$) | B ($3 \leq t < 5$) | C ($t \geq 5$) | P  |
|------------------------|-------------|---------------------|----------------|----|
| N (number)             | 30          | 97                  | 71             |    |
| Age (year-old)         | 69.37±15.3  | 69.6±15.8           | 74.3±13.4      | .105|
| Sex (M)                | 17 (56.7)   | 68 (70.1)           | 43 (60.6)      | .270|
| BMI                    | 24.9±3.9    | 23.3±3.5            | 23.9±4.0       | .176|
| BW (kg)                | 62.8±13.0   | 61.8±10.7           | 62.6±12.2      | .869|
| Comorbidity            |             |                     |                |    |
| CV                     | 17 (56.7)   | 49 (50.5)           | 48 (67.6)      | .086|
| CV                     | 4 (13.3)    | 8 (8.2)             | 2 (2.8)        | .139|
| Neurology              | 6 (20.0)    | 13 (13.4)           | 15 (21.1)      | .383|
| DM                     | 8 (26.7)    | 16 (16.5)           | 17 (23.9)      | .341|
| Malignancy             | 3 (10.0)    | 6 (6.2)             | 5 (7.0)        | .776|
| Malignancy             | 3 (10.0)    | 10 (10.3)           | 13 (18.3)      | .272|
| SBP (mmHg)             | 139.5±20.2  | 131.3±26.4          | 139.2±29.5     | .114|
| BT (˚C)                | 36.8±0.8    | 37.0±1.1            | 37.0±1.2       | .806|
| HR (/min)              | 86.5±18.7   | 82.5±19.9           | 84.4±18.3      | .588|
| RR (/min)              | 19.1±2.2    | 19.0±1.7            | 19.8±6.8       | .481|
| WBC (/cumm)            | 9462.3±4561.7 | 10634.4±6290.4  | 9522.8±5135.6 | .376|
| Hb (g/dL)              | 12.6±2.2    | 12.9±1.5            | 12.7±1.8       | .672|
| PLT (/cumm)            | 219285.7±111629.6 | 203684.2±71627.2 | 189676.1±77174.0 | .230|
| INR                    | 1.1±0.1     | 1.1±0.1             | 1.1±0.1        | .629|
| ALT (U/L)              | 170.0±302.4 | 228.1±229.4         | 173.5±174.3    | .235|
| AST (U/L)              | 211.9±580.3 | 251.1±268.6        | 229.5±263.2    | .855|
| BUN (mg/dL)            | 18.7±9.1    | 17.6±8.2            | 19.0±11.4      | .671|
| Cr (mg/dL)             | 1.1±0.6     | 1.2±0.6             | 1.3±1.6        | .587|
| ALP (U/L)              | 212.1±172.3 | 224.7±149.3         | 226.8±174.5    | .919|
| rGT (U/L)              | 321.6±340.9 | 373.2±298.8        | 331.6±355.6    | .653|
| Amy (mg/dL)            | 655.9±953.4 | 570.0±955.0      | 993.6±1538.4   | .372|
| Tbili (mg/dL)          | 3.2±2.7     | 3.6±3.8             | 3.1±2.7        | .617|
| CRP (mg/dL)            | 7.9±8.6     | 6.0±6.6             | 5.2±5.6        | .267|
| Antiplatelet           | 4 (13.3)    | 13 (13.4)           | 10 (14.1)      | .991|
| Anticoagulant          | 1 (3.3)     | 0 (0)               | 2 (2.8)        | .227|
| Blood culture          | 1 (3.3)     | 12 (12.4)           | 9 (12.7)       | .338|
| Blood culture          | 2 (6.7)     | 16 (16.5)           | 8 (11.3)       | .320|
| PTCD/PTGBD             | 1(3.3)      | 9 (9.3)             | 7 (9.9)        | .389|
| Previous Abdominal Surgery | 8 (26.7) | 28 (28.9)           | 24 (33.8)      | .707|
| Previous EST           | 0 (0)       | 4 (4.1)             | 4 (5.6)        | .421|
| Previous EPBD          | 0 (0)       | 1 (1.0)             | 3 (4.2)        | .241|

$t$: endoscopic papillary balloon dilatation duration time, $N$: number, BMI: body mass index, BW: body weight, CV: cardiovascular, CM: chest, DM: diabetes mellitus, SBP: systolic blood pressure, BT: body temperature, HR: heart rate, RR: respiratory rate, WBC: white blood cell count, Hb: hemoglobin, PLT: platelet, INR: international normalized ratio, ALT: alanine aminotransferase, AST: aspartate aminotransferase, BUN: blood urea nitrogen, Cr: creatinine, ALP: alkaline phosphatase, rGT: gamma-glutamyl transpeptidase, Amy: amylase, Tbili: total bilirubin, CRP: c-reactive protein, BD: bile duct, CBD: common bile duct, PTCD: percutaneous transhepatic cholangiography and drainage, PTGDB: percutaneous transhepatic gallbladder drainage, EST: endoscopic sphincterotomy, EPBD: endoscopic papillary balloon dilatation.

https://doi.org/10.1371/journal.pone.0233388.t001
Table 2. Findings during procedure.

| Group       | A (t < 3) | B (3 ≤ t < 5) | C (t ≥ 5) | P     |
|-------------|-----------|---------------|-----------|-------|
| N (number)  | 30        | 97            | 71        |       |
| CBD stone ≥ 10mm | 10 (33.3) | 26 (26.8)     | 38 (53.5) | .010  |
| Maximum CBD diameter (mm) | 15.1±5.0  | 14.8±4.8      | 16.2±5.1  | .175  |
| CBD stone size (mm)    | 9.1±4.2  | 8.2±3.8       | 11.0±5.7  | .003  |
| JPD         | 10 (33.3) | 41 (42.3)     | 35 (49.3) | .318  |
| Pus         | 2 (6.7)   | 3 (3.1)       | 4 (5.6)   | .632  |
| Sludge      | 5 (16.7)  | 26 (26.8)     | 19 (26.8) | .481  |
| Balloon size (mm) |         |               |           | .108  |
| 8           | 11        | 29            | 12        |       |
| 10          | 15        | 46            | 32        |       |
| 11          | 0         | 3             | 4         |       |
| 12          | 2         | 17            | 16        |       |
| 14          | 1         | 2             | 6         |       |
| 15          | 1         | 0             | 1         |       |
| EPLBD (>10mm) | 4 (13.3)  | 22 (22.7)     | 27 (38%)  | .017  |
| Complete removal | 30 (100%) | 97 (100%)     | 71 (100%) |       |
| Extraction Balloon | 10 (33.3) | 36 (37.1)     | 24 (33.8) | .876  |
| Retrieval Basket | 15 (50.0) | 56 (57.7)     | 47 (66.2) | .354  |
| Precut      | 0 (0)     | 0 (0)         | 0 (0)     | -     |
| Schendra    | 0 (0)     | 0 (0)         | 0 (0)     | -     |
| Lithotripsy | 0 (0)     | 2 (2.1)       | 5 (7.0)   | .118  |

CBD: common bile duct, JPD: juxtapapillary diverticulum, EPLBD: endoscopic papillary large balloon dilatation.

https://doi.org/10.1371/journal.pone.0233388.t002

Table 3. Post endoscopic papillary balloon dilatation complications.

| Group       | A (t < 3) | B (3 ≤ t < 5) | C (t ≥ 5) | P     |
|-------------|-----------|---------------|-----------|-------|
| N (number)  | 30        | 97            | 71        |       |
| Bleeding    | 0 (0)     | 2 (2.1)       | 0 (0)     | .349  |
| Perforation | 0 (0)     | 0 (0)         | 0 (0)     | -     |
| Pancreatitis| 4 (13.3)* | 3 (3.1)*      | 3 (4.2)   | .075  |
| BTI         | 0 (0)     | 4 (4.1)       | 6 (8.5)   | .175  |
| Aspiration Pneumonia | 0 (0)  | 0 (0)         | 1 (1.4)   | .407  |
| In hospital death | 0 (0)  | 0 (0)         | 0 (0)     | -     |

* P = 0.032 between Group A and B.

BTI: biliary tract infection.

https://doi.org/10.1371/journal.pone.0233388.t003

EPBD complications

Table 3 shows the complications after EPBD. Overall, there were no significant differences in the PEP rate between the three groups (13.3% vs. 3.1% vs. 4.2%, p = 0.075). However, the subgroup analysis showed that the group A patients had a significant higher PEP rate than the group B patients (13.3% vs. 3.1%, p = 0.032). There were no perforations or deaths that occurred in the three groups. The bleeding rate, post EPBD biliary tract infection, and aspiration pneumonia were not significantly different. In addition, there was no difference in biliary tract infection when compared the Group A (n = 0) with the Groups B and C together (n = 10) (p = 0.170).
Post-ERCP pancreatitis rate

We further analyzed the risk factor of post-EPBD pancreatitis (Table 4). In the univariate analysis, an age ≤ 75 years (p = 0.052), female (p = 0.094), total bilirubin ≤ 1.2 mg/dL (p = 0.096), CBD diameter < 10 mm (p = 0.051), difficult cannulation (p = 0.098), and dilatation duration < 3 minutes (p = 0.049) were possible risk factors of PEP. A further multivariate analysis showed that age ≤ 75 years (OR, 5.006; p = 0.057), CBD < 10 mm (OR, 5.332; p = 0.034), and dilatation duration < 3 minutes (OR, 4.942; p = 0.027) were still independent risk factors of post-EPBD pancreatitis. In 53 patients who received EPLBD, the dilatation time for a minimum of three minutes did not increase the PEP rate (0% vs. 4.5% vs. 0%, p = 0.488) (Table 5).

Discussion

The current consensus suggests EPBD as an alternative to EST for extracting CBD stones, especially in the presence of coagulopathy or altered anatomy [7]. However, the biggest

---

**Table 4. Univariate and multivariate analysis of post ERCP pancreatitis.**

|                        | Univariate Analysis | Multivariate Analysis |
|------------------------|---------------------|-----------------------|
|                        | PEP (+) n = 10      | PEP (-) n = 188       | P value | P value  | OR       | 95% CI |
| Age (≤75-year-old)     | 8/10 (80.0%)        | 91/188 (48.4%)        | .052    | .057     | 5.006    | 0.954–26.286 |
| Sex (male)             | 4/10 (40.0%)        | 124/188 (66.0%)       | .094    | NA       |
| Total bilirubin (≤ 1.2 mg/dL) | 5/10 (50.0%)   | 48/188 (25.5%)        | .096    | NA       |
| CBD < 10mm             | 3/10 (30.0%)        | 19/188 (10.1%)        | .051    | .034     | 5.332    | 1.134–25.058 |
| Pancreatic duct cannulation | 3/10 (30.0%)    | 36/188 (19.1%)        | .401    | NA       |
| JPD (+)                | 3/10 (30.0%)        | 83/188 (44.1%)        | .379    | NA       |
| Balloon size           |                     |                       | .577    | NA       |
| EPLBD (>10mm)          | 1/10 (10.0%)        | 52/188 (27.7%)        | .267    | NA       |
| Difficult cannulation* | 5/10 (50.0%)        | 49/188 (26.1%)        | .098    | NA       |
| CBD stone < 10mm       | 7/10 (70.0%)        | 92/188 (48.9%)        | .201    | NA       |
| Lithotripsy (+)        | 0/10 (0.0%)         | 7/188 (3.7%)          | .534    | NA       |
| Dilatation < 3min      | 4/10 (40.0%)        | 26/188 (13.9%)        | .049    | .027     | 4.942    | 1.194–20.447 |
| Dilatation < 5min      | 7/10 (70.0%)        | 120/188 (63.8%)       | .692    | NA       |
| Time                   |                     |                       | .332    | NA       |

ERCP: endoscopic retrograde cholangiopancreatography, PEP: post ERCP pancreatitis, OR: odds ratio, CI: Confidence interval, NA: not available, NS: not significant, CBD: common bile duct, JPD: juxtapapillary diverticulum, EPLBD: endoscopic papillary large balloon dilatation
*: cannulation attempts of duration > 5 minutes, > 5 attempts, or 2 pancreatic guidewire passages.

https://doi.org/10.1371/journal.pone.0233388.t004

---

**Table 5. Post endoscopic papillary balloon dilatation complication in EPLBD patients.**

| Group               | A (t < 3) | B (3 ≤ t < 5) | C (t ≥ 5) | P      |
|---------------------|-----------|---------------|-----------|--------|
| N (number)          | 4         | 22            | 27        | .017   |
| Bleeding            | 0 (0)     | 1 (4.5)       | 0 (0)     | .488   |
| Perforation         | 0 (0)     | 0 (0)         | 0 (0)     | -      |
| Pancreatitis        | 0 (0)     | 1 (4.5)       | 0 (0)     | .488   |
| BTI                 | 0 (0)     | 2 (9.1)       | 1 (3.7)   | .632   |
| Aspiration Pneumonia| 0 (0)     | 0 (0)         | 0 (0)     | -      |
| In hospital death    | 0 (0)     | 0 (0)         | 0 (0)     | -      |

EPLBD: Endoscopic papillary large balloon dilatation; BTI: Biliary tract infection.

https://doi.org/10.1371/journal.pone.0233388.t005
concern of EPBD was the increased rate of post-EPBD pancreatitis [2, 4, 5, 9, 10, 16]. Previous studies have demonstrated that the incidence of post-EPBD pancreatitis was 7.4–15.4% [2, 4, 5, 9]. The incidence of PEP in our study is 6.6%, which was better than that of previous studies. Liao et al. first demonstrated that a 5-minute EPBD reduces the risk of pancreatitis compared with the conventional 1-minute EPBD (4.8% vs. 15.1%, p = 0.038) [12]. Further systematic reviews showed that the duration of EPBD was inversely associated with pancreatitis risk [11]. Current clinical guideline suggests a EPBD duration of at least 2 minutes [7]. The mechanism of pancreatitis was thought to involve the compartment syndrome from the post-EPBD hemorrhage/edema of an uncut sphincter of Oddi [12, 17]. If the theory was true, the critical point of pancreatitis should be whether EPBD cause loosened sphincter ampullae, not the duration of the balloon dilatation. Our results showed that a dilatation time of at least 3 minutes with an adequate orifice opening did not increase the incidence of post-EPBD pancreatitis. Younger age was well-known as a risk factor of PEP [18], and post-EPBD compartment syndrome may explain why small CBD diameter was also an independent risk factor of pancreatitis.

The incidence of PEP in patients with EPLBD patients was 0.8–11.2% in previous studies [13, 14, 19]. However, none of the previous studies discussed the adequate duration of dilatation time in patients with EPLBD. The PEP incidence in patients with EPLBD was 1.9% in our study. The PEP rate were not significantly different among the three groups. All of our patients with EPLBD had their stones removed successfully, and EML was used in six of the patients (11.3%). Our results demonstrated that at least 3 minutes of dilatation duration may be enough for patients with EPLBD.

Recent studies have proven that prophylactic pancreatic stent placement had a significant reduction in incidence and severity of PEP, and pancreatic stent placement is recommended in patients who are at a high risk for PEP [20, 21]. In our study, no repeated inadvertent PD cannulation occurred, so we did not place any prophylactic stents in our patients. Non-steroidal anti-inflammatory drugs (NSAIDs) have also been shown to significantly reduce the incidence and severity of PEP [22–24]. Aggressive lactated Ringer’s (LR) hydration is thought to prevent further injury to the pancreas from microvascular hypoperfusion and activate pancreatic enzymes [25]. Our data was collected before these promising studies, so rectal NSAIDs or LR solution were not administered to patients in our study for PEP prevention. However, our PEP incidence was not higher than current studies. Whether longer EPBD duration plus pancreatic stent placement, rectal NSAIDs, and LR solution hydration would further decrease the PEP incidence is interesting and warrants additional investigation.

With respect of successful stone removal, Liu et al. analyzed 10 randomized control trials (RCTs), and demonstrated that EPBD has equivalently great success for complete stone removal to EST [5]. Zhao et al. reviewed 14 RCTs and showed that EPBD decreased the overall clearance of stones compared to EST [10]. It is generally acknowledged that EPBD is less likely to remove large CBD stone. In our study, we did not exclude the large CBD stones, and the proportion of large CBD stone was about one third (CBD stone ≥ 10mm, n = 74, 37.4%). The successful stone removal rate was 100%, and the utility of EML was 3.5% (n = 7). Although there was a higher proportion of large CBD stones in patients in group C, the successful stone removal rate did not decrease. Our study showed that large CBD stones may increase the duration of EPBD, but did not decrease the clearance of CBD stones. The results were consistent with those reported by Liu et al.

Additionally, a previous meta-analysis showed that the post-EPBD bleeding rate was less than 1% [10]. The post-EPBD bleeding rate in our study was 1%, and there were no significant differences among the three groups. Furthermore, there were no procedure related perforations that occurred in our study, similar with that of a previous meta-analysis [5].
There were some limitations to our study. Our study was not a randomized control trial. There may be some selection bias in the study. The time of EPBD was not standardized but was the choice of the endoscopist, this may also cause bias. It is also not current standard not to use a guidewire for primary cannulation nowadays. However, the relatively low rate of PEP reflected the acceptable experience of the endoscopist performing biliary cannulation without using a guidewire at that time. In addition, our data were collected during the period when use of NSAIDs or LR was still debatable for PEP prevention, thus, only the patients from 2010 to 2012 when no rectal NSAIDs or LR solution hydration use in our hospital were included. It is interesting to investigate whether dilatation time could further affect the occurrence of PEP in the period when rectal NSAIDs was frequently used in high risk PEP patients. Further studies are still needed to determine the adequate balloon dilatation duration.

Conclusions

An EPBD duration of more than 3 minutes with adequate orifice opened by an experienced endoscopist may be enough for PEP prevention. A small CBD diameter, young age and shorter dilatation duration could cause more PEP.

Acknowledgments

We would like to acknowledge the assistance of Mr. Dong-Ming Liao.

Author Contributions

Formal analysis: Chung-Kai Chou.
Investigation: Chung-Kai Chou, Kuei-Chuan Lee.
Methodology: Kuei-Chuan Lee.
Resources: Chung-Kai Chou, Kuei-Chuan Lee, Tseng-Shing Chen.
Supervision: Kuei-Chuan Lee, Jiing-Chyuan Luo, Tseng-Shing Chen, Chin-Lin Perng, Yi-Hsiang Huang, Han-Chien Lin, Ming-Chih Hou.
Writing – original draft: Chung-Kai Chou.
Writing – review & editing: Chung-Kai Chou, Kuei-Chuan Lee.

References

1. Minami A, Nakatsu T, Uchida N, Hirabayashi S, Fukuma H, Morshed SA, et al. Papillary dilation vs sphincterotomy in endoscopic removal of bile duct stones. A randomized trial with manometric function. Digestive diseases and sciences. 1995; 40(12):2550–2554. https://doi.org/10.1007/BF02220440 PMID: 8536511
2. Fujita N, Maguchi H, Komatsu Y, Yasuda I, Hasebe O, Igarashi Y, et al. Endoscopic sphincterotomy and endoscopic papillary balloon dilatation for bile duct stones: A prospective randomized controlled multicenter trial. Gastrointestinal endoscopy. 2003; 57(2):151–155. https://doi.org/10.1067/mge.2003.56 PMID: 12556774
3. Isayama H, Komatsu Y, Inoue Y, Toda N, Shiratori Y, Tsujino T, et al. Preserved function of the Oddi sphincter after endoscopic papillary balloon dilation. Hepato-gastroenterology. 2003; 50(54):1787–1791. PMID: 14696405
4. Baron TH, Harewood GC. Endoscopic balloon dilatation of the biliary sphincter compared to endoscopic biliary sphincterotomy for removal of common bile duct stones during ERCP: a metaanalysis of randomized, controlled trials. The American journal of gastroenterology. 2004; 99(8):1455–1460. https://doi.org/10.1111/j.1572-0241.2004.30151.x PMID: 15307859
5. Liu Y, Su P, Lin S, Xiao K, Chen P, An S, et al. Endoscopic papillary balloon dilatation versus endoscopic sphincterotomy in the treatment for choledocholithiasis: a meta-analysis. Journal of
gastroenterology and hepatology. 2012; 27(3):464–471. https://doi.org/10.1111/j.1440-1746.2011.06912.x PMID: 21913984

6. Yasuda I, Tomita E, Enya M, Kato T, Moriwaki H. Can endoscopic papillary balloon dilation really preserve sphincter of Oddi function? Gut. 2001; 49(5):686–691. https://doi.org/10.1136/gut.49.5.686 PMID: 11600473

7. Testoni PA, Mariani A, Aabakken L, Arvanitakis M, Bories E, Costamagna G, et al. Papillary cannulation and sphincterotomy techniques at ERCP: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2016; 48(7):657–683. https://doi.org/10.1055/s-0042-108641 PMID: 27299638

8. Lin CK, Lai KH, Chan HH, Tsai WL, Wang EM, Wei MC, et al. Endoscopic balloon dilatation is a safe method in the management of common bile duct stones. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2004; 36 (1):68–72.

9. Disario JA, Freeman ML, Bjorkman DJ, Macmathuna P, Petersen BT, Jaffe PE, et al. Endoscopic balloon dilatation compared with sphincterotomy for extraction of bile duct stones. Gastroenterology. 2004; 127(5):1291–1299. https://doi.org/10.1053/gastro.2004.07.017 PMID: 15520997

10. Zhao HC, He L, Zhou DC, Geng XP, Pan FM. Meta-analysis comparison of endoscopic papillary balloon dilatation and endoscopic sphincteroplasty. World journal of gastroenterology. 2013; 19 (24):3883–3891. https://doi.org/10.3748/wjg.v19.i24.3883 PMID: 23840129

11. Liao WC, Tu YK, Wu MS, Wang HP, Lin JT, Leung JW, et al. Balloon dilation with adequate duration is safer than sphincterotomy for extracting bile duct stones: a systematic review and meta-analyses. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastrological Association. 2012; 10(10):1101–1109.

12. Liao WC, Lee CT, Chang CY, Leung JW, Chen JH, Tsai MC, et al. Randomized trial of 1-minute versus 5-minute endoscopic balloon dilatation for extraction of bile duct stones. Gastrointestinal endoscopy. 2010; 72(6):1154–1162.

13. Chan HH, Lai KH, Lin CK, Tsai WL, Wang EM, Hsu PI, et al. Endoscopic papillary large balloon dilatation alone without sphincterotomy for the treatment of large common bile duct stones. BMC gastroenterology. 2011; 11:69. https://doi.org/10.1186/1471-230X-11-69 PMID: 21668994

14. Oh MJ, Kim TN. Prospective comparative study of endoscopic papillary large balloon dilatation and endoscopic sphincterotomy for removal of large bile duct stones in patients above 45 years of age. Scandinavian journal of gastroenterology. 2012; 47(8–9):1071–1077. https://doi.org/10.3109/00365521.2012.690046 PMID: 22934594

15. Staritz M, Ewe K, Meyer zum Buschenfelde KH. Endoscopic papilla dilatation, a possible alternative to endoscopic papillotomy. Lancet. 1982; 1(8284):1306–1307.

16. Natsui M, Saito Y, Abe S, Iwanaga A, Ikariishi S, Nozawa Y, et al. Long-term outcomes of endoscopic papilla balloon dilatation and endoscopic sphincterotomy for bile duct stones. Digestive endoscopy: official journal of the Japan Gastroenterological Endoscopy Society. 2013; 25(3):313–321.

17. Mac Mathuna P, Siegenberg D, Gibbons D, Gorin D, Afdhal NA, et al. The acute and long-term effect of balloon sphincteroplasty on papillary structure in pigs. Gastrointestinal endoscopy. 1996; 44(6):650–655. https://doi.org/10.1016/s0016-5107(96)70046-9 PMID: 8979052

18. Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, et al. Complications of endoscopic biliary sphincterotomy. The New England journal of medicine. 1996; 335(13):909–918. https://doi.org/10.1056/NEJM199609263351301 PMID: 8782497

19. Minakari M, Samani RR, Shavakhi A, Jafari A, Alijanian N, Hajaiikhani M. Endoscopic papillary balloon dilatation in comparison with endoscopic sphincterotomy for the treatment of large common bile duct stone. Advanced biomedical research. 2013; 2:46. https://doi.org/10.4103/2277-9175.114166 PMID: 24516846

20. Choudhary A, Bechtlold ML, Arif M, Szary NM, Puli SR, Othman MO, et al. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointestinal endoscopy. 2011; 73(2):275–282. https://doi.org/10.1016/j.gie.2010.03.039 PMID: 21295641

21. Mazaki T, Mado K, Masuda H, Shiono M. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: an updated meta-analysis. Journal of gastroenterology. 2014; 49(2):343–355. https://doi.org/10.1007/s00535-013-0806-1 PMID: 23612857

22. Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. The New England journal of medicine. 2012; 366(15):1414–1422. https://doi.org/10.1056/NEJMoa1111103 PMID: 22494121

23. Puig I, Calvet X, Baylina M, Isava A, Sort P, Liao J, et al. How and when should NSAIDs be used for preventing post-ERCP pancreatitis? A systematic review and meta-analysis. PloS one. 2014; 9(3):e92922. https://doi.org/10.1371/journal.pone.0092922 PMID: 24675922
24. Sethi S, Sethi N, Wadhwa V, Garud S, Brown A. A meta-analysis on the role of rectal diclofenac and indomethacin in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Pancreas. 2014; 43(2):190–197. https://doi.org/10.1097/MPA.000000000000090 PMID: 24518496

25. Buxbaum J, Yan A, Yeh K, Lane C, Nguyen N, Laine L. Aggressive hydration with lactated Ringer’s solution reduces pancreatitis after endoscopic retrograde cholangiopancreatography. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2014; 12(2):303–307 e301.